Nirsevimab, a long-acting monoclonal antibody, was introduced last season (2023–2024) in some countries with the aim of ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

Sanofi (NASDAQ:SNY) will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure widespread availability ahead of the ...

Nirsevimab implementation in Catalonia, Spain, reduced emergency department visits and hospital admissions for bronchiolitis ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

The announcement comes as part of WHO’s broader effort to reduce child mortality, particularly in low- and middle-income ...

A single injection of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) ...